The PANACEA phase Ib/II trial is currently investigating the use of pembrolizumab (KEYTRUDA®) in combination with trastuzumab, to determine whether the addition of an anti-PD-1 treatment can overcome trastuzumab resistance in patients with HER2-positive breast cancer whose cancer spread whilst they were on trastuzumab. This evidence concerns the gene ERBB2 and cancer.